Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LAPATINIB Cause Malignant neoplasm progression? 173 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 173 reports of Malignant neoplasm progression have been filed in association with LAPATINIB. This represents 8.7% of all adverse event reports for LAPATINIB.

173
Reports of Malignant neoplasm progression with LAPATINIB
8.7%
of all LAPATINIB reports
41
Deaths
21
Hospitalizations

How Dangerous Is Malignant neoplasm progression From LAPATINIB?

Of the 173 reports, 41 (23.7%) resulted in death, 21 (12.1%) required hospitalization, and 3 (1.7%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LAPATINIB. However, 173 reports have been filed with the FAERS database.

What Other Side Effects Does LAPATINIB Cause?

Diarrhoea (382) Disease progression (227) Palmar-plantar erythrodysaesthesia syndrome (182) Nausea (161) Metastases to central nervous system (160) Neutropenia (160) Vomiting (155) Asthenia (148) Fatigue (139) Off label use (118)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which LAPATINIB Alternatives Have Lower Malignant neoplasm progression Risk?

LAPATINIB vs LAPATINIB DITOSYLATE LAPATINIB vs LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN LAPATINIB vs LARONIDASE LAPATINIB vs LAROTRECTINIB LAPATINIB vs LASILIX

Related Pages

LAPATINIB Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression LAPATINIB Demographics